Comorbidities Incorporated to Improve Prediction for Prevalent Mild Cognitive Impairment and Alzheimer’s Disease in the HABS-HD Study.

Blood biomarkers have the potential to transform Alzheimer’s disease (AD) diagnosis and monitoring, yet their integration with common medical comorbidities remains insufficiently explored.